TipRanks
Advertisement
Advertisement

CH:GILD Stock Latest News

Nurix Therapeutics announces second research term extension with Gilead
The FlyNurix Therapeutics announces second research term extension with Gilead
15h ago
GILD
NRIX
Gilead put volume heavy and directionally bearish
PremiumThe Fly
Gilead put volume heavy and directionally bearish
5d ago
GILD
Michael Yee Reiterates Buy on Gilead, Highlighting Yeztugo-Driven HIV Growth and Maintaining Unchanged $175 Price Target
PremiumRatings
Michael Yee Reiterates Buy on Gilead, Highlighting Yeztugo-Driven HIV Growth and Maintaining Unchanged $175 Price Target
11d ago
GILD
Gilead announces expanded scope of licensing agreements for lenacapavir
PremiumThe Fly
Gilead announces expanded scope of licensing agreements for lenacapavir
20d ago
GILD
Gilead announces agreement with PAHO for lenacapavir access
PremiumThe Fly
Gilead announces agreement with PAHO for lenacapavir access
20d ago
GILD
Gilead price target raised to $175 from $155 at HSBC
PremiumThe FlyGilead price target raised to $175 from $155 at HSBC
26d ago
GILD
Assembly Biosciences exercises profit share option with Gilead for HSV program
Premium
The Fly
Assembly Biosciences exercises profit share option with Gilead for HSV program
27d ago
ASMB
GILD
Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV
Premium
The Fly
Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV
1M ago
GILD
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
PremiumThe Fly
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
1M ago
GILD
LKFT
Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination
PremiumThe Fly
Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination
1M ago
MRK
GILD
MacroGenics receives $10M milestone after Gilead exercises license option
PremiumThe Fly
MacroGenics receives $10M milestone after Gilead exercises license option
2M ago
GILD
MGNX
Gilead Sciences Earnings Call Highlights Strong Core Growth
PremiumCompany Announcements
Gilead Sciences Earnings Call Highlights Strong Core Growth
2M ago
GILD
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
PremiumRatingsGilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
2M ago
GILD
Gilead files automatic mixed securities shelf
Premium
The Fly
Gilead files automatic mixed securities shelf
2M ago
GILD
Gilead price target lowered to $150 from $156 at Truist
Premium
The Fly
Gilead price target lowered to $150 from $156 at Truist
2M ago
GILD
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
PremiumRatings
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
2M ago
GILD
Gilead price target raised to $123 from $120 at RBC Capital
PremiumThe Fly
Gilead price target raised to $123 from $120 at RBC Capital
2M ago
GILD
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
PremiumRatings
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
2M ago
GILD
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
PremiumRatings
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
2M ago
GILD
Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)
PremiumThe FlyGilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)
2M ago
GILD
Gilead raises FY26 EPS view to (65c)-(30c) from ($1.05)-(65c), consensus (75c)
Premium
The Fly
Gilead raises FY26 EPS view to (65c)-(30c) from ($1.05)-(65c), consensus (75c)
2M ago
GILD
Gilead update on California ruling removes an overhang, says UBS
Premium
The Fly
Gilead update on California ruling removes an overhang, says UBS
2M ago
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >